The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#EHA2024: Indolent and mantle cell NHL
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to indolent and mantle cell NHL, here.
CONGRESS #EHA2024 | Late-breaking | @michaelwangmd @MDAndersonNews reports phase 3 ECHO trial of acalabrutinib (A) plus bendamustine (B) and rituximab (R) vs placebo (P) BR in untreated MCL. N=598, mFU=17 mo, mPFS=66.4 mo & 49.6 mo with ABR & PBR, resp; P=0.0160. OS was positive… pic.twitter.com/Fmlqe3JVDF
— Lymphoma Hub (@lymphomahub) June 16, 2024
CONGRESS #EHA2024 | Umberto Vitolo reports 1st results from EPCORE NHL-1 FL cycle 1 optimization (C1 OPT) cohort investigating mitigation strategies for CRS with no mandatory hospitalization in pts with R/R FL receiving epcoritamab. N=86, primary endpoint, reduction in CRS, met… pic.twitter.com/iAgDBcBrBn
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Sarit Assouline presents subgroup analysis of phase II study evaluating mosunetuzumab monotherapy in high-risk pts with heavily pre-treated R/R FL. Durable remissions and clinically meaningful survival outcomes observed, including those with POD24 (3-year PFS… pic.twitter.com/415B2bVHnB
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Tycel Phillips, MD (@LymphClinician) from @cityofhope presented an updated analysis of the phase I/II study of glofitamab for R/R #mantlecelllymphoma, demonstrating high response rates and durable responses in both BTKi-treated and -naïve pts. Majority of… pic.twitter.com/lMBPEAz4nS
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Primary analysis of the phase II ELM-2 study demonstrates deep and durable responses with odronextamab (CD20×CD3 bispecific antibody) in heavily pretreated pts with R/R FL. Primary endpoint ORR, 80%; CR rate 73%; CR correlated with favorable PFS and OS at 24… pic.twitter.com/L302fO0fGL
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024
— Lymphoma Hub (@lymphomahub) June 16, 2024
Enrico Tiacci, University of Perugia, presents findings from the HCL-PG04 phase II trial of obinutuzumab monotherapy and combination with vemurafenib in patients with R/R hairy cell leukemia.
▪️ Safety profile of obinutuzumab as expected, mostly grade 1 (n=26)… pic.twitter.com/jR6Hje03Y9
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
